MedTrace Logo

Immune Signature Analysis of Disease Progression in Post Immunotherapy Lung Cancer Patients

NCT05415358 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 23

Last updated 2026-04-22

No results posted yet for this study

Summary

The purpose of this study is to examine the association between ctDNA/immune biomarkers and disease progression in patients who, at immunotherapy discontinuation, have completed at least 20 of an anticipated 24 months of immune checkpoint inhibitor monotherapy or immune checkpoint inhibitor combination chemotherapy for mNSCLC.

Conditions

  • Lung Cancer, Nonsmall Cell

Interventions

OTHER

Blood and tissue samples

Blood and tissue will be collected to perform ctDNA and immune biomarkers assessment to predict progression within 6 months of immune checkpoint inhibitor treatment discontinuation.

Sponsors & Collaborators

  • Atrium Health Levine Cancer Institute

    collaborator OTHER

  • Atrium Health Wake Forest Baptist

    collaborator OTHER

  • Wake Forest University Health Sciences

    lead OTHER

Principal Investigators

  • Kathryn Mileham, MD · Atrium Health Levine Cancer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-17
Primary Completion
2035-09-30
Completion
2035-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05415358 on ClinicalTrials.gov